Lysophospholipid profiles of apolipoprotein E-deficient mice reveal potential lipid biomarkers associated with atherosclerosis progression using validated UPLC-QTRAP-MS/MS-based lipidomics approach

Yan, Yingfei; Du, Zhifeng; Chen, Chang; Li, Jiaxin; Xiong, Xiang; Zhang, Yang; Jiang, Hongliang

doi:10.1016/j.jpba.2019.03.062

Cited by 12 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lyso-PLs have been correlated with the initiation and/or progression of atherosclerosis. 37 Saturated and monounsaturated molecular species of lyso-PLs accumulated in the serum of the HFD group in the present study, which is consistent with the results of previous studies. 38,39 Lyso-PLs exhibit pro-atherogenic properties by upregulating the expression of the leukocyte adhesion factor in coronary artery endothelial cells.…”

Section: Discussionsupporting

confidence: 93%

Lipidomics Approach in High-Fat-Diet-Induced Atherosclerosis Dyslipidemia Hamsters: Alleviation Using Ether-Phospholipids in Sea Urchin

Wang

Chen

Wang

et al. 2021

J. Agric. Food Chem.

View full text Add to dashboard Cite

Ether-phospholipids (ether-PLs) in sea urchins, especially eicosapentaenoic-acid-enriched plasmenyl phosphatidylethanolamine (PE-P) and plasmanyl phosphatidylcholine (PC-O), exhibit potential lipid-regulating effects. However, their underlying regulatory mechanisms have not yet been elucidated. Herein, we integrated an untargeted lipidomics strategy and biochemical analysis to investigate these mechanisms in high-fat-induced atherosclerotic hamsters. Dietary supplementation with PE-P and PC-O decreased total cholesterol and low-density lipoprotein cholesterol concentrations in serum. The lipid regulatory effects of PE-P were superior to those of PC-O. Additionally, 20 lipid molecular species, including phosphatidylethanolamine, cholesteryl ester, triacylglycerol, and phosphatidylinositol, were identified as potential lipid biomarkers in the serum of hamsters with PC-O and PE-P treatment (95% confidence interval; p < 0.05). The variations of lipids may be attributed to downregulation of adipogenesis genes and upregulation of lipid β-oxidation genes and bile acid biosynthesis genes. The improved lipid homeostasis by ether-PLs in sea urchins might be a key pathway underlying the antiatherosclerosis effect.

show abstract

Section: Discussionsupporting

confidence: 93%

Lipidomics Approach in High-Fat-Diet-Induced Atherosclerosis Dyslipidemia Hamsters: Alleviation Using Ether-Phospholipids in Sea Urchin

Wang

Chen

Wang

et al. 2021

J. Agric. Food Chem.

View full text Add to dashboard Cite

show abstract

“…Lui et al quantified 23 purines and pyrimidines in biological samples. Yan et al focused on the quantitation of 169 lysophospholipids in mouse samples. Sarafian et al studied the profile of 145 primary, secondary, and tertiary bile acids in plasma, serum, and urine samples.…”

Section: Discussionmentioning

confidence: 99%

Recent Developments along the Analytical Process for Metabolomics Workflows

et al. 2019

View full text Add to dashboard Cite

“…Elevated LPIs levels have also been reported in a quantitative pro ling study on high-fat dietfed apolipoprotein E-de cient mice. Compared with other LPLs, LPIs continuously accumulate with worsening of AS and are considered stable biomarkers of AS [45]. Because activation of GPR55 by LPIs can cause intracellular overload and increase calcium release to accelerate vascular calci cation, elevations in LPIs levels are regarded as triggers of AS [45].…”

Section: Discussionmentioning

confidence: 99%

Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients

Cao

Yang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Psoriasis is a common chronic inflammatory skin disease associated with overproduction of interleukin-17A (IL-17A). IL-17A monoclonal antibodies (mAbs) have shown clinical efficacy in psoriasis patients. Although a series of different overlapping mechanisms have been found to establish a link between psoriasis and cardiovascular diseases, the underlying mechanisms of the two types of diseases and the potential efficacy of IL-17A mAbs in amelioration of cardiovascular comorbidities remain unclear.Methods: Serum samples from two study cohorts including 117 individuals were analyzed using a high-throughput UHPLC-MS platform. Non-targeted metabolic profiling analysis was first conducted with samples from 28 healthy individuals and from 28 psoriasis patients before and after 12-weeks of ixekizumab treatment in study cohort 1. Study cohort 2 was additionally recruited to validate the correlations of the identified metabolites with cardiovascular diseases. Results: A total of 43 differential metabolites, including lysophospholipids, free fatty acids, acylcarnitines and dicarboxylic acids, were accurately identified in study cohort 1, and the analysis showed that lipid metabolism was impaired in psoriasis patients. Compared with healthy individuals, psoriasis patients had higher levels of lysophosphatidylcholines, lysophosphatidylinositols, lysophosphatidic acids and free fatty acids, but lower levels of acylcarnitines and dicarboxylic acids. The identified dicarboxylic acid levels were inversely correlated with psoriasis area and severity index (PASI) scores (P < 0.05). The results for study cohort 2 were largely consistent with the results for study cohort 1. Moreover, the levels of all identified lysophosphatidylcholines were higher in psoriasis patients with coronary heart diseases than in psoriasis without coronary heart disease. Notably, most of these lipidic changes were ameliorated by ixekizumab treatment.Conclusion: The results of this non-targeted metabolomic analysis indicate that treatment with IL-17A mAbs can not only ameliorate psoriasis lesions but also restore dysregulated lipid metabolism to normal levels in psoriasis patients. Considering that dysregulated lipid metabolism has been regarded as the critical factor in cardiovascular diseases, the recovery of lipid metabolites in psoriasis patients indicates that IL-17A mAbs might have the potential protective effects against cardiovascular comorbidities.

show abstract

Lysophospholipid profiles of apolipoprotein E-deficient mice reveal potential lipid biomarkers associated with atherosclerosis progression using validated UPLC-QTRAP-MS/MS-based lipidomics approach

Cited by 12 publications

References 43 publications

Lipidomics Approach in High-Fat-Diet-Induced Atherosclerosis Dyslipidemia Hamsters: Alleviation Using Ether-Phospholipids in Sea Urchin

Lipidomics Approach in High-Fat-Diet-Induced Atherosclerosis Dyslipidemia Hamsters: Alleviation Using Ether-Phospholipids in Sea Urchin

Recent Developments along the Analytical Process for Metabolomics Workflows

Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients

Contact Info

Product

Resources

About